Organon Soars 25% on Sun Pharma’s $12 Billion All-Cash Offer
Sun Pharma has submitted a binding $12 billion all-cash bid for Organon, implying a nearly 6.7× premium over its $1.8 billion market cap. Organon shares spiked 25% to $8.60, marking its largest-ever daily gain.
1. Binding $12B All-Cash Bid
Sun Pharma has submitted a binding $12 billion all-cash offer for Organon after three months of due diligence, marking its largest overseas acquisition pursuit to date. The proposed transaction, if finalized within coming weeks, secures financing commitments from multiple global banks.
2. Shares Soar on Acquisition News
Organon’s stock jumped 25% to $8.60 on the bid report, representing its biggest single-day gain on record and reflecting investor enthusiasm for a significant premium over its $1.8 billion market capitalization.
3. Strategic Rationale for Sun Pharma
The acquisition aligns with Sun Pharma’s goal to bolster its innovation-driven branded pharmaceuticals business and strengthens its presence in women’s health and specialty therapies, expanding its global footprint.
4. Organon’s Background and Challenges
Spun off from Merck in 2021, Organon focuses on reproductive health, contraception and fertility, with a broader portfolio across dermatology, neurology and cardiovascular. Recent governance challenges included the October 2025 CEO resignation tied to sales practice investigations.